Roger Illingworth, M.D., Ph.D., professor emeritus of medicine, passed away on Nov. 4. His death came at the end of a long struggle with a debilitating chronic illness. He was 68 years old.
Dr. Illingworth came to Portland from Liverpool, England where he earned a Ph.D. in biochemistry. His interests focused on the interaction between nutrition and the plasma lipid profile. He worked as a post-doctoral fellow in the laboratories of Drs. Bill and Sonja Connor. In 1973, he went to the University of Miami in the M.D./Ph.D. program, and returned to Portland in 1977 as assistant professor in the Department of Medicine, Division of Endocrinology, Diabetes, and Clinical Nutrition.
Over the course of his career, he became one of a small elite group of thought leaders in this discipline worldwide. He was a member of the NIH Nutrition Study section, a member of the Expert panel for the National Cholesterol Education program from its inception, a founding member of the American Board of Lipidology, and a long serving member of the Endocrine and Metabolic Disorders Advisory committee to the Food and Drug Administration.
Dr. Illingworth played a leading role in developing the LDL apheresis treatment modality and created that treatment option at OHSU. He played a central role in the early development of statin therapy for the treatment of arteriosclerosis. He was a national leader in academic medicine and contributed substantively to OHSU's academic community and reputation over the past 35 years.
"He has been, and will continue to be, missed by our faculty," said Lynn Loriaux, M.D., Ph.D.. professor of medicine and head of the Division of Endocrinology, Diabetes, and Clinical Nutrition.
Memorial services for Dr. Roger Illingworth will be held Sunday, December 8, at 1:30pm at the Multnomah Athletic Club. In lieu of flowers, donations may be given to the American Heart Association.